Providing a shorter infusion of the glycoprotein IIb/IIIa inhibitor (GPI) eptifibatide to patients undergoing PCI cuts costs and does not worsen outcomes, according to a single-center study published ...
Anthony A. Bavry, M.D., M.P.H.; Deepak L. Bhatt, M.D., F.A.C.C. Patients with stable and unstable coronary artery disease undergoing stenting were eligible for study ...
(March 30, 2009) (Orlando, Florida) — Routine early use of the GP IIb/IIIa blocker eptifibatide was not superior to delayed provisional use in the cath lab in high-risk ACS patients in the EARLY ACS ...
Glycoprotein IIb/IIIa inhibitors are indicated in patients with acute coronary syndromes who are undergoing an invasive procedure. The optimal timing of the initiation of such therapy is unknown. We ...
Intravenous thrombolysis is a standard treatment of acute ischemic stroke. The efficacy and safety of combining intravenous thrombolysis with argatroban (an anticoagulant agent) or eptifibatide (an ...
Evidence suggests that platelet reactivity can increase the risk of thrombosis and ischemic events after coronary stenting. The dose at which clopidogrel is most effective and whether the addition of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results